Picture of Novanta logo

NOVT — Novanta News Story

0.000.00%
us flag iconLast trade - 00:00
TechnologyAdventurousLarge CapHigh Flyer

Novanta Inc expected to post earnings of 63  cents a share - Earnings Preview

* Novanta Inc  NOVT.OQ   NOVT.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 10. 
    * The Bedford Massachusetts-based  company is expected to
report 
a 20.6% increase in revenue to $196.055 million from $162.58
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Novanta Inc is for
earnings of 63 cents per share. For the same quarter last year,
the company reported earnings of 58 cents per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Novanta Inc
is
$148​, above​ its last closing price of $127.49. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  0.64        0.64       0.67      Beat    4.3
 Sep. 30 2021  0.60        0.60       0.75      Beat    24.5
 Jun. 30 2021  0.51        0.51       0.62      Beat    22.2​
 Mar. 31 2021  0.39        0.39       0.58      Beat    49.7
 ​​Dec.        0.44        0.44       0.53      Beat    20.5
 31 2020                                                
 Sep. 30 2020  0.39        0.39       0.42      Beat    6.8​
 Jun. 30 2020  0.23        0.23       0.48      Beat    105.7
 Mar. 31 2020  0.32        0.32       0.51      Beat    57.7
 This summary was machine generated May 6 at 18:34 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Novanta

See all news